Received Oct 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
essential tremors; This non-serious case was reported by a consumer via call center representative and described the occurrence of essential tremor in a male patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. In MAR-2009, the patient received the 1st dose of Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced essential tremor (Verbatim: essential tremors). The outcome of the essential tremor was unknown. It was unknown if the reporter considered the essential tremor to be related to Boostrix and Boostrix Pre-Filled Syringe Device. It was unknown if the company considered the essential tremor to be related to Boostrix and Boostrix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Linked case(s) involving the same patient: US2025125448 Additional Information: GSK Receipt Date: 30-SEP-2025 The reporter described that having a diagnosis of essential tremors in 2009 that he believes is considered a neurological disorder, so was thought he was not supposed to receive the TDaP (claiming that the pertussis immunization caused the side effects).; Sender's Comments: GSK-US2025125448:Same patient/Different dose